Clinical Scorecard: Evaluating Neighborhood Exposomes and Their Links to Cancer Rates: Justification, Research Framework, and Methodological Approaches
At a Glance
Category
Detail
Condition
Colorectal, lung, and female breast cancer incidence
Key Mechanisms
Neighborhood disadvantage domains including socioeconomic deprivation, racial segregation, environmental pollutants, and built environment exposures over the life course
Target Population
Residents of Virginia and Pennsylvania with varying racial/ethnic backgrounds and residential histories
Care Setting
Population-based cancer registries and epidemiologic research settings
Key Highlights
Cancer disparities are influenced by cumulative neighborhood exposures over time, not just at diagnosis.
Neighborhood exposome comprises multiple domains that interact to affect cancer risk.
Residential mobility and timing of exposures are critical factors in assessing cancer risk related to neighborhood disadvantage.
Guideline-Based Recommendations
Diagnosis
Consider comprehensive residential histories to assess lifetime neighborhood exposures when evaluating cancer risk.
Management
Target interventions addressing socioeconomic deprivation, racial segregation, environmental pollutants, and built environment factors to reduce cancer disparities.
Monitoring & Follow-up
Use spatiotemporal data and longitudinal tracking of neighborhood exposures to monitor cancer risk factors over time.
Risks
Ignoring residential mobility and cumulative exposures may bias risk estimates and obscure key neighborhood-related cancer risk factors.
Patient & Prescribing Data
Individuals with varied residential histories in Virginia and Pennsylvania, including diverse racial/ethnic groups
Understanding neighborhood exposome exposures can inform targeted prevention strategies to reduce cancer incidence disparities.
Clinical Best Practices
Incorporate multi-domain neighborhood exposure assessments in cancer risk evaluations.
Account for temporal changes and residential mobility in exposure measurement.
Utilize population-based cancer registry data linked with detailed residential histories for comprehensive risk analysis.
Tamoxifen is commonly prescribed in hormone receptor-positive breast cancer but also associated with weight gain, which can complicate survivorship care. This narrative review summarizes evidence on tamoxifen-associated weight gain and outlines pharmacologic weight management options in this population.
